Analyst consensus rating
BioMarin Pharmaceutical Analyst Rating: Buy
BMRN is rated Buy by 26 analysts with a $91.04 target. As of 2026-08-30.
Direct answer
BioMarin Pharmaceutical's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $91.04.
Forecast evidence checked August 30, 2026.
Get free BioMarin Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $64.67
- Average price target
- $91.04
- High price target
- $124.00
- Low price target
- $59.00
- Low target gap
- -8.8%
- Target upside
- +40.8%
- High target gap
- +91.8%
- Target range width
- 100.5%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioMarin Pharmaceutical?
BioMarin Pharmaceutical has a verified Buy consensus. The same dataset has an average price target of $91.04.
How far are BioMarin Pharmaceutical's low and high targets from the recorded price?
The low target implies -8.8%, while the high target implies +91.8%.
How many analysts are included in BioMarin Pharmaceutical's consensus?
The verified consensus includes 26 analysts.
How is BioMarin Pharmaceutical's target upside or downside calculated?
The average target of $91.04 is divided by the recorded price of $64.67, then one is subtracted to produce +40.8%. This does not guarantee a future return.
When was BioMarin Pharmaceutical's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.